NuVaisve launches biologic for posterolateral spine surgery in US: 5 key notes

Spinal Tech

NuVaisve launched AttraX Putty, the newest addition to its biologics portfolio, in the United States.

Here are five things to know about the technology:


1. The synthetic bone graft product is indicated for use as an autograft extender in posterolateral spine surgery.


2. The AttraX Putty is designed with a biotextured surface to drive bone regeneration.


3. Surgeons have already used the technology in 20,000 patients worldwide and invested in clinical studies to demonstrate performance when compared with other synthetic bone graft options for challenging posterolateral cases in animal models.


4. In the studies, AttraX Putty had increased bone formation and mechanically stronger fusions when compared with Vitoss BA and Actifuse ABX.


5. The technology received FDA clearance in October 2015; it’s been used globally since 2011.


“AttraX Putty has shown promising results in pre-clinical models, highlighted by increased bone formation when compared with traditional osteoconductive synthetic scaffolds,” said Robert Eastlack, MD, an orthopedic surgeon at Scripps Clinic in La Jolla, Calif. The significant clinical experience with AttraX Putty outside the United States and extensive scientific pre-clinical study is an exciting and promising combination.”

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers